The Pharmaceutical Market: Poland

Date: January 31, 2013
Pages: 102
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P9C5C80F57BEN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Poland
OVERVIEW OF THE PHARMACEUTICAL MARKET IN POLAND

The Polish pharmaceutical market contracted severely in 2012 , owing to harsh pricing measures and strict margins imposed on wholesalers, pharmaceutical makers and retailers. Moreover, over the course of the year, the burden of pharmaceutical spending has shifted towards the Polish consumer , as the harsher reimbursement regime has caused private contributions to prescription payments rise. We forecast a return to growth in 2013, driven by private consu mption as the Polish government entrenches cuts to drug expenditure. We expect strong growth in the mediu m to long term as Poland's economy diversifies and aligns with developed countries. The growth of private medical companies is a positive development in the Polish healthcare market, and the possible introduction of voluntary health insurance could lead to a greater role for the private sector in healthcare provision.

Headline Expenditure Projections

Pharmaceuticals: PLN33.37bn (US$11.26bn) in 2011 to PLN31.38bn (US$9.62bn) in 2012; -5.98% in local currency terms and -14.5 % in US dollar terms.

Healthcare: PLN112.18bn (US$37.85bn) in 2011 to PLN118.57bn (US$36.37bn) in 2012; +5.2% in local currency terms and -5.5% in US dollar terms.

Medical devices: PLN6.80bn (US$2.29bn) in 2011 to PLN7.10bn (US$2.18bn) in 2012; +4.5% in local currency terms and -5.0% in US dollar terms. Local currency fo recast has risen since Q 4 12, while the US dollar forecast has fallen.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    Poland Pharmaceuticals Industry SWOT
    Poland Political SWOT
    Poland Economic SWOT
    Poland Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

    Table: Central And Eastern Europe Pharmaceuticals Risk/Reward Ratings, Q113
    Rewards
    Risks

POLAND – MARKET SUMMARY

REGULATORY REGIME

    Advertising Regulations
    Other Regulatory Developments
    Intellectual Property Regime
    Intellectual Property Shortcomings
    Pricing And Reimbursement Regime
    Pricing Policies
    Drug Price Inflation
    Reimbursement Policies
    Reimbursement Regime Changes

INDUSTRY TRENDS AND DEVELOPMENTS

    Epidemiology
    Healthcare System
    Hospital Infrastructure
    Ambulatory Infrastructure
    Table: Civilian Outpatient Facilities, 2002-2009
    Hospital Privatisation
    Health Insurance
    Distribution Channels
    EU Directive
    Drug Wholesaling
    Leading Wholesalers
    ACP Pharma
    Cefarm
    Table: Cefarm’s Financial Indicators, 2007-2010 (Million Zlotys)
    Phoenix Pharma Polska
    Pelion Healthcare Group
    Research & Development
    Clinical Trials
    Developments In The Clinical Trials Sector
    Medical Devices

INDUSTRY FORECAST SCENARIO

    Overall Market Forecast
    Table: Pharmaceutical Sales, Historical Data and Forecasts
    Key Growth Factors – Healthcare
    Table: Healthcare Expenditure Trends, Historical Data and Forecasts
    Table: Government Healthcare Expenditure Trends, Historical Data and Forecasts
    Table: Private Healthcare Expenditure Trends, Historical Data and Forecasts
    Key Growth Factors – Macroeconomic
    Table: Long-Term Macroeconomic Forecasts
    Prescription Drug Market Forecast
    Table: Prescription Drug Market Indicators, Historical Data and Forecasts
    Patented Drug Market Forecast
    Table: Patented Drug Market Indicators, Historical Data and Forecasts
    Generic Drug Market Forecast
    Table: Poland Generics Drug Market Indicators, Historical Data and Forecasts
    OTC Medicine Market Forecast
    Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts
    Pharmaceutical Trade Forecast
    Table: Pharmaceutical Trade Data And Forecasts (US$mn)
    Table: Pharmaceutical Trade Data And Forecasts (PLNmn)
    Medical Device Market Forecast
    Table: Medical Device Market Indicators, Historical Data and Forecasts

COMPETITIVE LANDSCAPE

    Pharmaceutical Industry
    Domestic Industry
    Domestic Company Developments
    Foreign Industry
    Foreign Company Developments
    Pharmaceutical Wholesale Sector
    Pharmaceutical Retail Sector
    Table: Number Of Pharmacies In Poland, 2004-2009

COMPANY PROFILES

    Local Companies
    Polpharma
    Bioton
  Multinational Companies
    GlaxoSmithKline
    Eli Lilly
    Gedeon Richter
    Krka
    Lek (Sandoz/Novartis)

DEMOGRAPHIC OUTLOOK

    Table: Population By Age Group, 1990-2020 (‘000)
    Table: Population By Age Group, 1990-2020 (% of total)
    Table: Key Population Ratios, 1990-2020
    Table: Rural And Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

    How We Generate Our Pharmaceutical Industry Forecasts
    Pharmaceutical Risk/Reward Ratings Methodology
    Ratings Overview

TABLE: PHARMACEUTICAL RISK/REWARD INDICATORS

WEIGHTING

TABLE: WEIGHTING OF COMPONENTS

SOURCES
Skip to top


Ask Your Question

The Pharmaceutical Market: Poland
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: